indole-3-carbinol
Indole-3-carbinol (I3C, C9H9NO) is produced by the breakdown of the glucosinolate glucobrassicin, which can be found at relatively high levels in cruciferous vegetables such as broccoli, cabbage, cauliflower, brussels sprouts, collard greens and kale. It is also available in dietary supplements. Indole-3-carbinol is the subject of on-going biomedical research into its possible anticarcinogenic, antioxidant, and anti-atherogenic effects. Research on indole-3-carbinol has been conducted primarily using laboratory animals and cultured cells. Limited and inconclusive human studies have been reported. A recent review of the biomedical research literature found that "evidence of an inverse association between cruciferous vegetable intake and breast or prostate cancer in humans is limited and inconsistent" and "larger randomized controlled trials are needed" to determine if supplemental indole-3-carbinol has health benefits. — Wikipedia
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2002 (NCT00033345)
Timeline
Indications
Mechanism of action
- Estrogen receptor alphaINHIBITOR
ESR1 inhibitor
Chemistry & pharmacology
SMILES
OCc1c[nH]c2ccccc12- Mol. weight
- 147.18 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIndole-3-carbinol ↗
- ChEMBLCHEMBL155625 ↗
Also known as
- 1h-indole-3-methanol
- 3-hydroxymethylindole
- i3c cpd
- indole-3-carbinol
- indole-3-carbinol
- indole-3-carbinol
- indole-3-carbinol
- indole-3-methanol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07164183 | Phase 3 | Sep 11, 2025 | Alcea |
| NCT03687073 | Phase 1 | Nov 30, 2018 | University of Minnesota |
| NCT00988845 | Phase 2 | Sep 1, 2009 | University of Wisconsin |
| NCT00607932 | N/A | Mar 1, 2005 | National Cancer Institute (NCI), Vanderbilt University |
| NCT00100958 | Phase 1 | Nov 1, 2004 | National Cancer Institute (NCI), University of Kansas |
| NCT00033345 | Phase 1 | Jan 1, 2002 | National Cancer Institute (NCI), University of Kansas |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 2002 |
| University of Kansas | Academic/Hospital | 2 | 2 | 1 | 2002 |
| Alcea | For profit | 1 | 1 | 1 | 2025 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2009 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2005 |